This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Expected Incidence of Tardive Dyskinesia Associated With Atypical Antipsychotics

William M. Glazer, MD

Published: April 30, 2000

Article Abstract

Given the problematic nature of tardive dyskinesia in persons taking conventional antipsychotics,evaluation of newer atypical antipsychotic agents should include a systematic assessment of tardive dyskinesialiability. Results of a prospective double-blind, randomized study of schizophrenic patients whoparticipated in 3 preclinical olanzapine studies and were treated with 5 to 20 mg/day of olanzapine(N = 1192) or haloperidol (N = 522) recently indicated a significantly lower risk of development of tardivedyskinesia with olanzapine treatment than haloperidol treatment. This article discusses the knowneffects of atypical antipsychotic medications on tardive dyskinesia movements (both withdrawal and persistent)and the incidence rate of tardive dyskinesia among schizophrenic patients undergoing long-termtreatment with olanzapine or haloperidol.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 61

Quick Links: Neurologic and Neurocognitive , Neurology

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...